EIF4E and lymphoma: Interestingly, silvestrol did not show anti-lymphoma activity (alone or with doxorubicin) in an Eμ-Myc/Bcl2 model, suggesting that eIF4A inhibition specifically counters the in vivo growth of malignant B cells with a strong drive for translational dysregulation (i.e., either by activation of mTORC1 signaling downstream of PTEN loss or by enforced expression of eIF4E) but not suppression of apoptosis per se by BCL2.